Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$520MCash, Jun 2026
26moCash Runway (est.)
+31%Share Count, 1 Year
Follow IMNM by emailGet an email when IMNM pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about IMNM, unsubscribe in one click. Privacy
💊 Upcoming FDA Decisions
PDUFA Date
Drug
Indication
Type
PoA
2027-04-28
—
adults with desmoid tumors and assigned a PDUFA target actio
NDA
63%
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area and cash runway. Not investment advice. See the full PDUFA calendar →
📣 What IMNM Says Is Next
late 2026 · “Preclinical ADC Pipeline : Immunome expects to submit Investigational New Drug applications (INDs) for IM-1340 and IM-1335 in mid- and late 2026, respectively.”
Company press release, Aug 11, 2026 · SEC filing
in 2026 · “Immunome expects to present initial lymphoma data for IM-1021 in 2026.”
Company press release, Aug 11, 2026 · SEC filing
by the end of 2026 · “Immunome plans to submit a Marketing Authorization Application to the European Medicines Agency for varegacestat by the end of 2026.”
Company press release, Aug 11, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
IMNM reported $520M in cash and short-term investments (as of Jun 30, 2026) and used about $60.7M/quarter in operations, an estimated runway of 25.7 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMNM and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.